Back to Search
Start Over
Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy
- Source :
- Clinical Kidney Journal, 13(5), 855-866. Oxford University Press, Clinical Kidney Journal
- Publication Year :
- 2020
-
Abstract
- Background End-stage renal disease (ESRD) is strongly associated with cardiovascular disease (CVD) risk. Advanced glycation endproducts (AGEs) and dicarbonyls, major precursors of AGEs, may contribute to the pathophysiology of CVD in ESRD. However, detailed data on the courses of AGEs and dicarbonyls during the transition of ESRD patients to renal replacement therapy are lacking. Methods We quantified an extensive panel of free and protein-bound serum AGEs [N∈-(carboxymethyl)lysine (CML), N∈-(carboxyethyl)lysine (CEL), Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine (MG-H1)], serum dicarbonyls [glyoxal (GO), methylglyoxal (MGO), 3-deoxyglucosone (3-DG)] and tissue AGE accumulation [estimated by skin autofluorescence (SAF)] in a combined cross-sectional and longitudinal observational study of patients with ESRD transitioning to dialysis or kidney transplantation (KTx), prevalent dialysis patients and healthy controls. Cross-sectional comparisons were performed with linear regression analyses, and courses following renal replacement therapy were analysed with linear mixed models. Results Free and protein-bound AGEs, dicarbonyls and SAF were higher in chronic kidney disease (CKD) Stage 5 non-dialysis (CKD 5-ND; n = 52) and CKD Stage 5 dialysis (CKD 5-D; n = 35) than in controls (n = 42). In addition, free AGEs, protein-bound CML, GO and SAF were even higher in CKD 5-D than in CKD5-ND. Similarly, following dialysis initiation (n = 43) free and protein-bound AGEs, and GO increased, whereas SAF remained similar. In contrast, following KTx (n = 21), free and protein-bound AGEs and dicarbonyls, but not SAF, markedly declined. Conclusions AGEs and dicarbonyls accumulate in uraemia, which is even exaggerated by dialysis initiation. In contrast, KTx markedly reduces AGEs and dicarbonyls. Given their associations with CVD risk in high-risk populations, lowering AGE and dicarbonyl levels may be valuable.
- Subjects :
- medicine.medical_specialty
STRESS
medicine.medical_treatment
EXTENDED HEMODIALYSIS
030232 urology & nephrology
Urology
kidney transplantation
030204 cardiovascular system & hematology
urologic and male genital diseases
End stage renal disease
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
PENTOSIDINE
DIALYSIS
medicine
METHYLGLYOXAL LEVELS
Renal replacement therapy
Pentosidine
AcademicSubjects/MED00340
Kidney transplantation
Dialysis
dicarbonyls
Transplantation
end-stage renal disease
PLASMA
business.industry
dialysis, dicarbonyls
SKIN AUTOFLUORESCENCE
Original Articles
RESIDUAL KIDNEY-FUNCTION
medicine.disease
Uremia
PRODUCTS
chemistry
Nephrology
CARDIOVASCULAR-DISEASE
Hemodialysis
business
advanced glycation endproducts
Kidney disease
Subjects
Details
- Language :
- English
- ISSN :
- 20488505
- Database :
- OpenAIRE
- Journal :
- Clinical Kidney Journal, 13(5), 855-866. Oxford University Press, Clinical Kidney Journal
- Accession number :
- edsair.doi.dedup.....9d023c9d14634b439cc37191cfbce2bd